BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22173067)

  • 1. Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone.
    Hofman J; Ahmadimoghaddam D; Hahnova L; Pavek P; Ceckova M; Staud F
    Pharmacol Res; 2012 Mar; 65(3):312-9. PubMed ID: 22173067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Olomoucine II, but not purvalanol A, is transported by breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1).
    Hofman J; Kučera R; Cihalova D; Klimes J; Ceckova M; Staud F
    PLoS One; 2013; 8(10):e75520. PubMed ID: 24116053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro.
    Cihalova D; Hofman J; Ceckova M; Staud F
    PLoS One; 2013; 8(12):e83467. PubMed ID: 24376706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs).
    Hofman J; Kučera R; Neumanova Z; Klimes J; Ceckova M; Staud F
    Xenobiotica; 2016; 46(5):416-23. PubMed ID: 26364927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro.
    An R; Hagiya Y; Tamura A; Li S; Saito H; Tokushima D; Ishikawa T
    Pharm Res; 2009 Feb; 26(2):449-58. PubMed ID: 18841444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
    Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
    Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
    Kim M; Turnquist H; Jackson J; Sgagias M; Yan Y; Gong M; Dean M; Sharp JG; Cowan K
    Clin Cancer Res; 2002 Jan; 8(1):22-8. PubMed ID: 11801536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein).
    Sim HM; Lee CY; Ee PL; Go ML
    Eur J Pharm Sci; 2008 Nov; 35(4):293-306. PubMed ID: 18725288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
    Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
    Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
    Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
    Cihalova D; Ceckova M; Kucera R; Klimes J; Staud F
    Biochem Pharmacol; 2015 Dec; 98(3):465-72. PubMed ID: 26300056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP).
    González-Sarrías A; Miguel V; Merino G; Lucas R; Morales JC; Tomás-Barberán F; Alvarez AI; Espín JC
    J Agric Food Chem; 2013 May; 61(18):4352-9. PubMed ID: 23586460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A high-throughput cell-based assay for inhibitors of ABCG2 activity.
    Henrich CJ; Bokesch HR; Dean M; Bates SE; Robey RW; Goncharova EI; Wilson JA; McMahon JB
    J Biomol Screen; 2006 Mar; 11(2):176-83. PubMed ID: 16490770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C.
    González-Lobato L; Real R; Prieto JG; Alvarez AI; Merino G
    Eur J Pharmacol; 2010 Oct; 644(1-3):41-8. PubMed ID: 20655304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance.
    Ifergan I; Scheffer GL; Assaraf YG
    Cancer Res; 2005 Dec; 65(23):10952-8. PubMed ID: 16322243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport.
    Zhang F; Throm SL; Murley LL; Miller LA; Steven Zatechka D; Kiplin Guy R; Kennedy R; Stewart CF
    Biochem Pharmacol; 2011 Jul; 82(1):24-34. PubMed ID: 21459080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of phosphoinositide-3 kinase pathway down regulates ABCG2 function and sensitizes malignant pleural mesothelioma to chemotherapy.
    Fischer B; Frei C; Moura U; Stahel R; Felley-Bosco E
    Lung Cancer; 2012 Oct; 78(1):23-9. PubMed ID: 22857894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein.
    Valdameri G; Pereira Rangel L; Spatafora C; Guitton J; Gauthier C; Arnaud O; Ferreira-Pereira A; Falson P; Winnischofer SM; Rocha ME; Tringali C; Di Pietro A
    ACS Chem Biol; 2012 Feb; 7(2):322-30. PubMed ID: 22039929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.